Login / Signup

Economic model of albumin infusion in septic shock: The EMAISS study.

Bertrand GuidetIdir GhoutJacques RopersPhilippe Aegerter
Published in: Acta anaesthesiologica Scandinavica (2020)
Based on the risk reduction observed in the septic shock subgroup analysis of the ALBIOS dataset, the application of the ALBIOS trial results to Cub-Réa data may suggest that albumin infusion is likely cost-effective in septic shock.
Keyphrases
  • septic shock
  • low dose
  • phase iii
  • electronic health record
  • randomized controlled trial
  • phase ii
  • double blind
  • placebo controlled